Share This

Related Topics News -

     
 Detail   |   Print 
     
藥明巨諾瑞基奧侖賽注射液初步臨床數據顯示安全性良好
2024-05-30T  
《公司業績》藥明巨諾-B全年虧損收窄至7.68億元人民幣
2024-03-20T  
國家醫保局:納入醫保藥品以五年內獲批新藥為主
2024-02-26T  
藥明系續受壓 藥明生物及藥明康德逆市續挫4%至5%
2024-01-29T  
藥明巨諾(02126.HK)倍諾達新適應症上市許可申請獲受理
2024-01-05T  
藥明巨諾(02126.HK)與2seventy bio簽訂獨家合作協議
2024-01-03T  
藥明巨諾首席財務官辭任
2023-12-17T  
藥明系股價全線反彈 藥明合聯(02268.HK)回升7.5%
2023-12-06T  
藥明系全面捱沽 藥明合聯曾瀉18%
2023-12-04T  
醫藥股個別造好 翰森、來凱及君實升6%-8% 藥明系受壓
2023-11-30T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.